Upstream Bio, Stock Current Liabilities
| UPB Stock | 19.19 0.26 1.34% |
Upstream Bio, fundamentals help investors to digest information that contributes to Upstream Bio,'s financial success or failures. It also enables traders to predict the movement of Upstream Stock. The fundamental analysis module provides a way to measure Upstream Bio,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Upstream Bio, stock.
Upstream |
Upstream Bio, Company Current Liabilities Analysis
Upstream Bio,'s Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Upstream Bio, has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Upstream Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Upstream Bio,'s direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Upstream Bio, could also be used in its relative valuation, which is a method of valuing Upstream Bio, by comparing valuation metrics of similar companies.Upstream Bio, is currently under evaluation in current liabilities category among its peers.
About Upstream Bio, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Upstream Bio,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Upstream Bio, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Upstream Bio, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Upstream Bio, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Upstream Bio,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Upstream Bio, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Upstream Bio, Stock:Check out Upstream Bio, Piotroski F Score and Upstream Bio, Altman Z Score analysis. For information on how to trade Upstream Stock refer to our How to Trade Upstream Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Upstream Bio,. If investors know Upstream will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Upstream Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Upstream Bio, is measured differently than its book value, which is the value of Upstream that is recorded on the company's balance sheet. Investors also form their own opinion of Upstream Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Upstream Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Upstream Bio,'s market value can be influenced by many factors that don't directly affect Upstream Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Upstream Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Upstream Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Upstream Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.